Crinetics Pharmaceuticals (CRNX) Expected to Announce Quarterly Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.92) per share and revenue of $0.73 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Crinetics Pharmaceuticals Stock Performance

Shares of NASDAQ CRNX traded up $0.62 during mid-day trading on Friday, reaching $37.48. 928,933 shares of the company traded hands, compared to its average volume of 970,180. The company's fifty day moving average is $43.49 and its two-hundred day moving average is $50.69. Crinetics Pharmaceuticals has a fifty-two week low of $34.07 and a fifty-two week high of $62.53. The stock has a market cap of $3.48 billion, a PE ratio of -10.05 and a beta of 0.56.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other news, insider Dana Pizzuti sold 5,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $39.07, for a total value of $195,350.00. Following the sale, the insider now owns 31,748 shares in the company, valued at approximately $1,240,394.36. The trade was a 13.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.00% of the company's stock.

Analyst Upgrades and Downgrades

CRNX has been the topic of a number of recent analyst reports. JMP Securities reissued a "market outperform" rating and issued a $87.00 price target on shares of Crinetics Pharmaceuticals in a research report on Monday, December 16th. TD Cowen began coverage on shares of Crinetics Pharmaceuticals in a report on Tuesday, February 11th. They issued a "buy" rating on the stock. HC Wainwright reissued a "buy" rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday, January 13th. Citigroup raised their price target on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the company a "buy" rating in a research report on Thursday, November 14th. Finally, Jefferies Financial Group raised Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price objective for the company in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $72.64.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.